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Abstract Current guidelines suggest the use of low doses of
acetylsalicylic acid (ASA) for patients with diabetes mellitus
(DM) in primary prevention. However, the evidences dem-
onstrating the beneficial effect of ASA in primary prevention
are conflicting. In this pilot study, we evaluated in a group of
diabetic patients, in primary prevention, the impact of ASA
treatment on oxidative stress and vascular function. We
enrolled 22 newly diagnosed diabetic patients, without any
previous clinical evidence of cardiovascular disease, to
receive, in primary prevention, ASA (100 mg/daily). We
tested, in basal condition, after 4 weeks of ASA administra-
tion and after 4 weeks of pharmacological washout, the
impact of ASA treatment on endothelial function, assessed by
a semipletysmographic method, measuring the main oxida-
tive stress parameters related to it. As expected, after 4 weeks
of treatment, ASA induced a significant reduction of plasma
thromboxane-A2, as a consequence of cyclooxygenase-1
inhibition. By contrast, ASA significantly increased the
plasma and urine 8-iso-PGF2a, a well-known prothrombotic
molecule, parallel to an increase of plasma NOX2 levels. The
enhancement of this oxidative pathway is associated with a
significant impairment of endothelial vasodilation, assessed
by reactive hyperemia index (RHI). The pharmacological
washout reverted all parameters to basal condition. Our
findings suggest that ASA utilization for primary prevention
in diabetic patients causes a significant increase of oxidative
stress burden impairing the vascular function. Present data, if
confirmed on a larger population, could permanently dis-
courage the use of the ASA for the primary prevention in
patients with DM.
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Introduction
Diabetes mellitus (DM) represents one of the most
important cardiovascular (CV) risk factors since diabetic
patients have an increased risk, two- to fourfold greater, to
develop coronary artery disease, myocardial infarction,
heart failure, peripheral artery disease, and sudden death [1,
2]. Atherosclerosis is the most important pathogenetic
mechanism explaining the relationship between DM and
CV events. It recognizes as the primum movens the endo-
thelial dysfunction, a condition characterized by the
reduction of the nitric oxide (NO) bioavailability inducing
the impairment of endothelium-mediated vasodilation and
the activation of proinflammatory and proliferative
pathways.
Hyperglycemia and insulin resistance, present in dia-
betic disease, induce endothelial dysfunction by several
mechanisms, including the advanced glycation end pro-
ducts (AGEs) synthesis, the activation of polyol and hex-
osamine pathways, and the diabetic dyslipidemia pattern
(formation of small and dense low-density lipoprotein
(LDL) particles and reduction of high-density lipoprotein
cholesterol (HDL-C)), all factors that promote the oxida-
tion/inflammation processes in the vasculature wall [3, 4].
Moreover, a marked increase in oxidative stress, char-
acterized by the overproduction of reactive oxygen species
(ROS), has been observed in diabetic patients [5]. The
catalytic subunit of the NADPH oxidase (NOX) enzyme
NOX2 is the most important cellular source of ROS, which
are able to react with various molecules. In particular, the
reaction of ROS with arachidonic acid of cell membranes,
leads to production of isoprostanes which, in turn, induce
platelet aggregation, vasoconstriction and stimulate the
inflammatory cascade in the vasculature, all pathogenic
mechanisms involved in endothelial dysfunction [6, 7]. The
platelet isoprostane 8-iso-PGF2a is a vasoconstrictor and
platelet activator formed by non-enzymatic oxidation
reaction between arachidonic acid and ROS. There are
evidences demonstrating that diabetic patients have an
upregulation of NOX2 compared to healthy controls, thus
presenting higher levels of ROS and 8-iso-PGF2a [8].
Acetylsalicylic acid (ASA), an inhibitor of cyclooxy-
genase-1 (COX1) that prevents platelet thromboxane (Tx)-
A2 formation [9, 10], used at low dose (100 mg/daily) in
secondary CV prevention, is able to reduce clinical events
in patients with coronary and peripheral artery disease and
DM. In fact, platelet Tx-A2 overproduction, and the sub-
sequent reduction obtained with aspirin administration, has
been demonstrated in diabetic patients [11]. Because
diabetic patients are characterized by a high CV risk profile,
similar to those who have already had a major CV event
(myocardial infarction or stroke), it has been proposed the
use of ASA for patients with DM also in primary prevention
[12, 13]. The American Diabetes Association, for example,
recommends the use of ASA in primary prevention in dia-
betic patients with 10-year CV risk[10 % (men[50 years
or women aged[60 presenting at least one additional major
risk factor, such as family history of coronary artery disease,
smoking, dyslipidemia, hypertension, or albuminuria) [14].
However, the beneficial effect of ASA in primary preven-
tion is still unclear [15]. In fact, there are recent evidences
that attribute to ASA a negative effect on oxidative stress-
related parameters in diabetic patients [16]. Particularly, an
oxidative stress-mediated platelet isoprostane overproduc-
tion occurs in aspirin-treated diabetic patients that is asso-
ciated with the attenuation of aspirin-mediated Tx-A2
inhibition, effect promoting platelet recruitment. Moreover,
the NOX2 upregulation observed in diabetic subjects con-
tributes to the ASA-induced formation of 8-iso-PGF2a in
both platelets and urine [8] that, in turn, increases the bur-
den of oxidative stress.
Although increasing evidences demonstrate a negative
impact of ASA on oxidative stress, in primary prevention
in diabetic patients, it remains uncertain whether this bio-
logical effect is followed, in turn, by functional alterations
that contribute to an increased risk of developing athero-
sclerosis. Because these contrasting evidences, in a recent
statement, the FDA expressed an unfavorable opinion to
the use of ASA for the primary prevention of heart attack
and stroke (http://www.fda.gov/Drugs/ResourcesForYou/
Consumers/ucm390574.htm), by underlying the serious
risks of bleeding in the stomach and brain associated with
the use of ASA without an effective therapeutic usefulness.
Thus, in this study, we evaluated, in a group of newly
diagnosed type 2 diabetic patients, the effect of ASA on
endothelium-dependent vasodilation and oxidative stress
burden, testing the hypothesis that ASA administration
(100 mg/daily) in primary prevention is able to increase the
oxidation parameters leading to endothelial dysfunction.
Materials and methods
Study population
According to statistical sample size calculation, we enrol-
led 22 newly diagnosed type 2 diabetic patients, diagnosed
by an oral glucose tolerance test (OGTT) [17], without any
clinical evidence of CV diseases. We excluded patients
with history of acute vascular events, cardiac arrhythmia or
congestive heart failure, type 1 DM, chronic kidney disease
or serum creatinine level C1.5 mg/dL, history of cancer,
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infections, smoke, chronic treatment with non-steroidal
antiinflammatory drugs, statins, and antiplatelet drugs, in
the previous 6 months. At the time of enrollment and
during the whole study, all patients were free from any
pharmacological treatment. After the enrollment, patients
started a 4-week treatment with 100 mg/daily of ASA (T1),
followed by a washout period of 4 weeks (T2). The
assessment of endothelial function and oxidative stress
parameters were performed at baseline and at the end of T1
and T2. Adherence to the treatment was assessed by the
pill-count method. The Ethical Committee of University
Magna Graecia of Catanzaro approved the protocol, and
informed written consent was obtained from all partici-
pants. All the investigations were performed in accordance
with the principles of the Declaration of Helsinki.
For this study, we did not include the control group for
two reasons: at first, because patients were control of
themselves; secondly, we preferred not exposing subjects




All materials were from Sigma-Aldrich unless otherwise
specified.
Blood sampling
After a 12-h fast, blood samples were taken. At 08:00 a.m.,
patients underwent routine biochemical analysis including
total cholesterol, HDL cholesterol, LDL cholesterol, tri-
glyceride, glucose, and creatinine. Samples, obtained from
patients after supine rest for at least 10 min, were taken in
tubes with 3.8 % sodium citrate and centrifuged at 300 rpm
for 15 min to obtain supernatant. Plasma samples were
immediately stored at -80 C.
Tx-A2 and NOX2 quantification
Human Tx-A2 Elisa Kit (Bio-medical assay) and enzyme-
linked immunosorbent assay kit for cytocrome b-245 b
polypeptide (cloud-clone corp) were used, respectively, for
plasma Tx-A2 and NOX2 quantitative determinations.
Serial dilutions at different concentrations of the standard
are prepared. Samples are centrifuged at 1,000 rpm for
10 min, and supernatants are used for the assay. The
human Tx-A2 and NOX2 polyclonal antibodies are pre-
coated into 96-well plate. Hundred microliters of standard
or samples was added into each well and incubated 90 min
at 37 C. Plate was washed twice with TBS washing buf-
fer; then, 100 ll of working solution, containing
biotinylated antihuman Tx-A2 and antihuman NOX2
detection antibodies (dilution 1:100), was added and
incubated at 37 C for 60 min. The plate was washed with
TBS 3 times and, after 100 ll Avidin–Biotin–Peroxidase
Complex (dilution 1:100) addiction, incubated at 37 C for
30 min. The plate was washed 5 times with TBS, and 90 ll
of TMB color developing agent was added, and then the
plate was incubated at 37 C for 15 min, in the absence of
light. At the end, 100 ll of stop solution is added to stop
the reaction. The intensity of the color change was mea-
sured spectrophotometrically with VictorTM X4 multi-label
plate reader at the wave length of 450 nm. The standard
curve was plotted as the relative optical density (OD) 450
of each standard solution versus the respective concentra-
tion of the standard solution. The human Tx-A2 and NOX2
concentration of the samples were interpolated from the
standard curve, using curve expert 1.4.
Human 8-isoprostane quantification
OxiselectTM 8-iso-prostaglandin F2a (8-iso-PGF2a)
ELISA kit (Cell Biolabs, INC.) was used for quantitative
determination of human 8-isoprostane in plasma and
urines. Hydrolysis of lipoprotein or phospholipid coupled
8-iso-PGF2a is required to measure both free and esterified
isoprostane. To hydrolyze these ester bounds, plasma was
treated with 1 part of 10 N NaOH for every 4 parts of
liquid samples and incubated for 2 h at 45 C. Then,
100 ll of 10 N HCl per 500 ll of hydrolyzed sample is
added. These samples were centrifuged for 5 min at
12,000 rpm, and supernatant was used in the assay. Urine
samples were acidified to pH 3 by adding 1/10 volume of
1 N HCl. Different serial dilutions of the standard were
prepared. Hundred microliters of diluted antiisoprostane
antibody (1:1,000) was added to the goat antirabbit anti-
body coated plate and incubated 1 h at 25 C on an orbital
shaker. The plate was washed 5 times with wash buffer.
Fifty-five microliters of standard or samples and 55 ll of
8-isoprostane-HRP conjugate were combined in a micro-
tube, mixing thoroughly. Hundred microliters of the com-
bined solution was transferred per well and incubated 1 h
at 25 C on an orbital shaker. The plate was washed 5
times with wash buffer; then 100 ll of substrate solution
was added to each well and incubated at room temperature
for 20 min on an orbital shaker. The enzyme reaction was
stopped by adding 100 ll of stop solution to each well.
Immediately, we read absorbance of each well on VictorTM
X4 multi-label plate reader at the wave length of 450 nm.
The standard curve was plotted as the relative (OD)
450 mm of each standard solution versus the respective
concentration of the standard solution. The human 8-iso-
prostane concentration of the samples was interpolated
from the standard curve.
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Endothelial function
Endothelial function was evaluated by a semipletysmo-
graphic method, with the measurement of digital pulse
volume amplitude (PVA). PVA was measured with the
subjects placed in the supine position, in a quiet, temper-
ature-controlled environment set at 22 C. A peripheral
arterial tonometer (PAT) was used to measure PVA in the
fingertip of the index finger (Itamar-Medical, Caesarea,
Israel). The peripheral arterial tonometer apparatus consists
of a finger-mounted probe that surrounds the fingertip with
an electronically controlled, inflatable, pressurized air
cushion confined within a rigid external case. The pressure
changes within the probe that accompany PVA changes in
the fingertip is transmitted to a personal computer where
the signal is band-pass filtered (0.3–30 Hz), amplified,
displayed, and stored. PVA was analyzed at rest and during
reactive hyperemia (RH). RH was elicited by the release of
an upper arm blood pressure cuff inflated above systolic
pressure for 5 min. Digital PVA–RH was calculated as the
ratio of the average PVA over a one-minute time interval
starting 1 min after cuff deflation (RH) divided by the
average PVA measured for 1 min before cuff inflation
(baseline) (RH index, RHI). The PVA from the index finger
of the other, non-ischemic hand (which was not subject to
RH), was measured continuously throughout the study to
assess any drift in the magnitude of the signal due to sys-
temic factors.
Statistical analysis
We computed the minimum sample size with respect to a
two-tailed one-sample Student’s t test, considering: a dif-
ference for RHI variation to be detected between baseline
and after ASA treatment, |d| C15 %; standard deviation of
the paired differences, SD = 0,11; and type 1 error prob-
ability a = 0.05 and power 1_b = 0.90 (0.80). Differences
among different times for the oxidative stress parameters,
(in particular, urinary and plasma 8-iso-PGF2a, plasma Tx-
A2 and NOX2), and vascular function were evaluated by
ANOVA for repeated measures. Chi-squared test will be
utilized for categorical variables. Data are reported as
mean ± SD. Differences were assumed to be significant at
P \ 0.05. All comparisons were performed using the Sta-
tistical Package of Social Science (SPSS) version 16.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
Study population
In Table 1, we reported the anthropometric, biochemical,
and hemodynamic characteristics of the study population,
expressed as mean ± SD. As evident, the group consists of
11 men and 11 women (mean age 59.6 ± 6.5 years) with
mean blood pressure values of 134.7/83.4 mmHg. More-
over, lipid profile showed mild hypercholesterolemia and
hypertriglyceridemia, consistent with their clinical condi-
tion of DM. No significant differences were observed at the
end of study (Table 1).
Effects of ASA treatment on Tx-A2 and 8-iso-PGF2a
levels
The antiplatelet effect of ASA, evaluated by plasma Tx-A2
measurement, was observed after 4 weeks of treatment
(from 8.25 ± 1.45 to 6.95 ± 1.08 pg/ml, P = 0.013). At
Table 1 Anthropometric,
biochemical, and hemodynamic
characteristics of the study
population in basal
BMI body mass index, SBP
systolic blood pressure, DBP
diastolic blood pressure, PP
pulse pressure
Basal End of study P
Gender (m/f) 11/11 11/11 –
Age (years) 59.6 ± 6.5 59.6 ± 6.5 –
BMI (kg/m2) 29.3 ± 2.6 29.0 ± 3.1 0.808
SBP (mmHg) 134.7 ± 11.0 130.5 ± 14.7 0.457
DBP (mmHg) 83.4 ± 9.0 81.0 ± 11.4 0.590
PP (mmHg) 51.3 ± 9.7 49.5 ± 12.8 0.714
Total cholesterol (mg/dl) 208.8 ± 22.5 202.3 ± 17.7 0.460
HDL cholesterol (mg/dl) 42.7 ± 10.7 38.7 ± 10.3 0.382
LDL cholesterol (mg/dl) 139.2 ± 23.7 141.8 ± 26.5 0.811
Triglyceride (mg/dl) 134.5 ± 36.8 108.5 ± 42.7 0.142
Fasting glucose (mg/dl) 124.0 ± 38.0 122.4 ± 24.2 0.907
Fasting insulin (mU/ml) 20.9 ± 6.6 19.3 ± 4.9 0.526
HOMA index 6.0 ± 1.7 5.9 ± 1.4 0.882
HbA1c (%; mmol/mol) 6.5 ± 0.9; 48.0 ± 2.7 6.4 ± 1.2; 46.0 ± 3.6 0.827
Creatinine (mg/dl) 0.9 ± 0.4 0.8 ± 0.7 0.685
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the end of pharmacological washout, Tx-A2 levels signifi-
cantly increased, reaching almost basal values (Fig. 1). As
observed in Fig. 2, treatment with ASA 100 mg/day
induced a significant increase in plasma (from
173.0 ± 13.5 to 187.5 ± 14.8 lg/ml, P = 0.009) and
urine (79.5 ± 17.5 to 107.0 ± 15.5 lg/ml, P \ 0.0001)
8-iso-PGF2a, respectively. Discontinuation of treatment
for 4 weeks (washout) resulted in a significant reduction in
8-iso-PGF2a levels, similar to that observed in baseline
conditions (Fig. 2).
Effects of ASA treatment on NOX2 levels
Four weeks administration of ASA was able to induce a
NOX2 overexpression. In particular, NOX2 levels
increased in plasma samples, from 7.93 ± 0.57 to
8.75 ± 1.38 ng/ml (P = 0.010). Interestingly, after the
washout period, NOX2 levels decreased, returning nearly
to basal levels (Fig. 3).
Effects of ASA treatment on endothelial function
Effects of ASA treatment on vascular function, expressed
by RHI, are shown in Fig. 4. As observed, the adminis-
tration of 100 mg/day of ASA induced, already after
1 week, a significant reduction of the vasodilatory response
to ischemia that reached the maximal reduction after
4 weeks of treatment (RHI from 1.72 ± 0.30 to
1.33 ± 0.26, P \ 0.0001); normal value C 1.67. After
4 weeks of pharmacological washout, endothelial function
was completely restored, with average values of RHI
similar to that observed in basal conditions
(RHI = 1.75 ± 0.17).
Discussion
In this study, we evaluated, in a group of newly diagnosed
type 2 diabetic patients, the impact of ASA treatment in
primary prevention on oxidative stress and vascular func-
tion. We demonstrated that ASA administration induces a
significant increase in global oxidative burden, as shown by
the increase of plasma and urine 8-iso-PGF2a, a well-
known proaggregating and prothrombotic molecule [18].
As already speculated, the increase of 8-iso-PGF2a could
Fig. 1 Effects of ASA on plasma levels of Tx-A2 in diabetic patients.
ASA treatment induced a significant reduction of Tx-A2 levels, as
consequence of COX1 inhibition. * = P \ 0.05 by ANOVA for
repeated measures
Fig. 2 Effects of ASA on urinary a and plasma b levels of 8-iso-
PGF2a in diabetic patients. ASA treatment was able to induce a
significant increase of 8-iso-PGF2a levels with a reduction after
4 weeks of drug washout. * = P \ 0.05 by ANOVA for repeated
measures
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be promoted, indirectly, by the ASA-induced inhibition of
the COX1 enzyme that, in turn, leads to the triggering of an
escape pathway of isoprostanes formation [16, 19]. More-
over, in diabetic patients, there is per se an increased
activity of the NADPH oxidase that is responsible for the
increased production of ROS [8], which are able to interact
with arachidonic acid to form isoprostanes [20]. ASA
treatment is also able to increase NOX2 levels, contributing
to cellular oxidative burden in ROS production. In this
way, the treatment with ASA, by selectively inhibiting
COX1, prevents the arachidonic acid contribution to gen-
erate Tx-A2, favoring the switch of the substrate for the
isoprostanes production [21]. According to this, our data
show that ASA induces a significant reduction in plasma
Tx-A2 and increases the plasma and urinary levels of 8-iso-
PGF2a (Fig. 5). Of interest, Gonc¸alves and corkers
recently reported that concomitant use of metformin and
ASA in diabetic patients can reduce levels of urinary bio-
markers of oxidative stress [22], offering new important
therapeutic implications for antidiabetic drugs.
The most relevant data of our study are the demon-
stration that ASA treatment in type 2 diabetic patients
causes a significant reduction in the endothelium-depen-
dent vasodilatory response. The reduction of RHI, already
occurred after 1 week of treatment, which reached patho-
logical values after 4 weeks, demonstrates that the ASA-
increased oxidative stress could adversely affect the vas-
cular function, by inhibiting its vasodilatory properties in a
setting of patients considered at high CV risk also in pri-
mary prevention. This finding has an important clinical
implication, because endothelial dysfunction represents a
powerful negative prognostic factor in different setting of
patients, including the uncomplicated hypertensive patients
that are considered at low risk in comparison with diabetic
ones [23]. Moreover, the impairment of endothelial func-
tion might worse the metabolic control since endothelial
dysfunction interacts with some different molecular path-
ways involved in the appearance of new diabetes [3, 24].
These results are clinically relevant because, according
to current evidences of the literature, there is still no
unanimous opinion about the real need of ASA treatment
for the primary cardiovascular prevention [25]. Our data
show that in DM, in which oxidative stress plays a pivotal
role in the pathogenesis of vascular damage, the treatment
with aspirin may increase the oxidative stress burden,
worsening in turn the vascular function. This negative
effect of ASA could have an important impact, especially
in diabetic patients who undergo percutaneous coronary
angioplasty and stenting, for whom the association of ASA
with another antiplatelet agent is recommended. This
treatment, on the basis of our findings, could be potentially
dangerous because it reduces the NO bioavailability with a
consequent worsening of vascular function. Moreover, our
results contribute to clarify an important pathophysiologi-
cal mechanism with a relevant clinical application because
they consent to better interpret the controversial results
obtained in primary prevention of diabetic patients [15].
This is further supported by the fact that ASA, beyond the
observed negative impact on vascular function, increases
the bleeding risk, mainly in subjects without previous CV
events in which a clear benefit of ASA utilization is not
clearly demonstrated. Our results differ from those reported
by Raghavan et al. [26], but these differences are due to the
methods and study population characteristics. In fact, these
Authors evaluated diabetic patients treated with statins,
Fig. 3 Effects of ASA on NOX2 plasma levels in diabetic patients.
ASA treatment was able to induce a significant increase of NOX2
levels, which returned to basal values after 4 weeks of pharmacolog-
ical washout. * = P \ 0.05 by ANOVA for repeated measures
Fig. 4 Effects of ASA on endothelium-dependent vasodilation
assessed by reactive hyperemic index (RHI). ASA treatment in
diabetic subjects caused a significant reduction of endothelial
vasodilatory response to ischemia; after the washout period, RHI
values were similar to those observed in basal condition. P \ 0.0001
by ANOVA for repeated measures
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antidiabetic, and antihypertensive drugs, while our patients
were newly diagnosed and without any pharmacological
treatment. In addition, the Authors evaluated total antiox-
idant status and blood total glutathione, while we investi-
gated the specific pathway involving NOX2 that is
overexpressed in diabetic patients.
Thus, present data, if confirmed on a larger study popula-
tion, could permanently discourage the use of the ASA for the
primary prevention in patients with DM, providing also new
targets for future research in the prevention and treatment of
oxidative stress and endothelial dysfunction related to it.
Study limitations
The most relevant limitation of the study is the small
number of patients, even if the statistical power size cal-
culation is satisfied. This is due to the fact that the patients
were enrolled at the first time of diagnosis of DM, after
performing an OGTT. In addition, the aim of this study was
to investigate a pathophysiological mechanism; thus, this
study could be considered a pivotal one, and not an inter-
ventional one. The short duration of observation period
(4 weeks) could be another limitation of the study. How-
ever, the demonstration that ASA induces a short-term
negative effect, by the increase of oxidative stress and
related endothelial dysfunction, could have relevant path-
ophysiological implications in the initial phases of vascular
injury, such as in the restenosis after percutaneous coronary
intervention.
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Fig. 5 Diagram graphically
reports the effects of ASA on
vascular oxidative stress leading
to endothelial dysfunction.
COX1 inhibition triggers an
escape pathway that is able to
promote the production of
isoprostanes that, in turn,
contribute to impair the
endothelium-dependent
vasodilation
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